193 related articles for article (PubMed ID: 24443791)
1. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
[TBL] [Abstract][Full Text] [Related]
2. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
4. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
[TBL] [Abstract][Full Text] [Related]
5. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
7. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
8. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.
Cioppi F; Cianferotti L; Masi L; Giusti F; Brandi ML
Clin Cases Miner Bone Metab; 2017; 14(2):123-130. PubMed ID: 29263719
[TBL] [Abstract][Full Text] [Related]
9. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
10. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.
Laskaratos FM; Walker M; Naik K; Maragkoudakis E; Oikonomopoulos N; Grant L; Meyer T; Caplin M; Toumpanakis C
Br J Cancer; 2016 Nov; 115(11):1321-1327. PubMed ID: 27811856
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
[TBL] [Abstract][Full Text] [Related]
14. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.
Saglam S; Hacisahinogullari H; Ozturk N; Kapran Y; Gulluoglu M; Turkmen C; Adalet I; Orhan Bilge A; Cem Balci N
J BUON; 2015; 20(5):1201-5. PubMed ID: 26537065
[TBL] [Abstract][Full Text] [Related]
18. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
[TBL] [Abstract][Full Text] [Related]
19. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
[TBL] [Abstract][Full Text] [Related]
20. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
